Open Orphan has announced the signing of a new contract with Codagenix Inc, a vaccine developer, to conduct a phase 1 trial for a COVID-19 vaccine candidate. The trial will focus on evaluation of safety and immunogenicity of the single-dose intranasal candidate in 48 volunteers. Although this is a phase I trial, in our view, it goes some way to validate Open Orphan's offering in the market and could lead to follow-on contracts. We expect the opportunity available to Open Orphan continues to inc ....
28 Jul 2020
COVID-19 Vaccine Ph I Trial Contract Signed
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
COVID-19 Vaccine Ph I Trial Contract Signed
hVIVO plc (HVO:LON) | 29.0 0 0.3% | Mkt Cap: 197.3m
- Published:
28 Jul 2020 -
Author:
Andrew Simms -
Pages:
5
Open Orphan has announced the signing of a new contract with Codagenix Inc, a vaccine developer, to conduct a phase 1 trial for a COVID-19 vaccine candidate. The trial will focus on evaluation of safety and immunogenicity of the single-dose intranasal candidate in 48 volunteers. Although this is a phase I trial, in our view, it goes some way to validate Open Orphan's offering in the market and could lead to follow-on contracts. We expect the opportunity available to Open Orphan continues to inc ....